Beclometasone Dipropionate Aqueous Nasal Spray, 50 micrograms per spray Malta - English - Medicines Authority

beclometasone dipropionate aqueous nasal spray, 50 micrograms per spray

generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - beclometasone dipropionate - nasal spray, solution - beclometasone dipropionate 50 µg - nasal preparations

HFA-134A BECLOMETASONE DIPROPIONATE AUTOHALER 50 %v/v Pressurised Inhalation Soln Ireland - English - HPRA (Health Products Regulatory Authority)

hfa-134a beclometasone dipropionate autohaler 50 %v/v pressurised inhalation soln

3m health care limited - beclometasone dipropionate - pressurised inhalation soln - 50 %v/v

QVAR 50 Israel - English - Ministry of Health

qvar 50

abic marketing ltd, israel - beclometasone dipropionate - inhaler - beclometasone dipropionate 50 mcg/dose - beclometasone - beclometasone - prophylaxis and treatment of bronchial asthma in adults and children 5 years of age and obove.

Nasobec 50 Micrograms Aqueous Nasal Spray Ireland - English - HPRA (Health Products Regulatory Authority)

nasobec 50 micrograms aqueous nasal spray

teva b.v. - beclometasone dipropionate - nasal spray, suspension - 50 microgram(s) - beclometasone

Becotide Evohaler 50 micrograms, Pressurised Inhalation Solution Ireland - English - HPRA (Health Products Regulatory Authority)

becotide evohaler 50 micrograms, pressurised inhalation solution

glaxosmithkline (ireland) limited - beclometasone dipropionate - pressurised inhalation, solution - 50 microgram(s) - glucocorticoids; beclometasone

Clenil Modulite 50 micrograms per metered dose Pressurised Inhalation Solution Ireland - English - HPRA (Health Products Regulatory Authority)

clenil modulite 50 micrograms per metered dose pressurised inhalation solution

chiesi limited - beclometasone dipropionate - pressurised inhalation, solution - 50 microgram(s) - glucocorticoids; beclometasone

Clenil Modulite 50 micrograms per metered dose Pressurised Inhalation Solution Ireland - English - HPRA (Health Products Regulatory Authority)

clenil modulite 50 micrograms per metered dose pressurised inhalation solution

chiesi farmaceutici s.p.a. - beclometasone dipropionate - pressurised inhalation, solution - 50 microgram(s) - glucocorticoids; beclometasone

Becotide Evohaler 50 micrograms, Pressurised Inhalation Solution Ireland - English - HPRA (Health Products Regulatory Authority)

becotide evohaler 50 micrograms, pressurised inhalation solution

imbat limited - beclometasone dipropionate - pressurised inhalation, solution - 50 microgram(s) - glucocorticoids; beclometasone

HFA-134A BECLOMETASONE DIPROPIONATE 50 %v/v Pressurised Inhalation Soln Ireland - English - HPRA (Health Products Regulatory Authority)

hfa-134a beclometasone dipropionate 50 %v/v pressurised inhalation soln

3m health care limited - beclometasone dipropionate - pressurised inhalation soln - 50 %v/v

FOSTAIR 100/6 beclometasone dipropionate 100 microgram and formoterol fumarate dihydrate 6 microgram pressurised inhalation solution Australia - English - Department of Health (Therapeutic Goods Administration)

fostair 100/6 beclometasone dipropionate 100 microgram and formoterol fumarate dihydrate 6 microgram pressurised inhalation solution

chiesi australia pty ltd - beclometasone dipropionate, quantity: 100 microgram; formoterol fumarate dihydrate, quantity: 6 microgram - inhalation, pressurised - excipient ingredients: norflurane; ethanol absolute; hydrochloric acid - asthma fostair is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ics) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ics and long-acting beta2-agonists (laba). (see section 4.2 dose and method of administration for treatment approaches). copd (fostair 100/6 only) symptomatic treatment of adults with severe copd (fev1 less than 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.